Serious side effects are rare when GLP-1 is properly prescribed and monitored
Accessing microdose concentrations Standard pharmaceutical GLP-1 products are not designed for microdosing
Retatrutide has shown greater average weight loss than Mounjaro in separate clinical trials, but it is not currently approved or available
Novo Nordisk, the manufacturer of Wegovy, also provides a tool that allows you to check your insurance coverage
Qualitative and mixed-methods research has demonstrated that patients perspectives provide valuable insights into medication effects, shifting expectations, experiences of stigma, and evolving identity [83,84,85]
For Canadians researching peptide options, Retatrutide offers several advantages beyond raw efficacy